









Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C™) platform which easily plug-and-plays multiple types of linker-payloads through site-specific conjugation process without compromising conjugation efficiency and casting minimal impact on antibody binding capacity. This platform has potential to increase the targeted delivery with improved efficacy.
ADVANCING THE NEXT GENERATION OF IMMUNOTHERAPY
GlobeNewswire